Temitayo A. Ogunleye, MD
Dermatology
Accepting new patients
Sees patients age 18 and up
Penn Dermatology University City
View 1 additional location
Schedule onlineCall 215-662-8060
Penn Medicine Provider

About me

  • Professor of Clinical Dermatology

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Albert Einstein Medical Center
  • Residency: University of Michigan Health

What my patients think about me

Average Rating

1534 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
March 2026
she is very professional
Anonymous
March 2026
she's the best
Anonymous
March 2026
she is a nice friendly and knowledgeable dr
Anonymous
March 2026
thorough

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Ogunleye is a Penn Medicine physician. In New Jersey, providers are affiliated with Penn Medicine through Clinical Health Care Associates of New Jersey or Princeton Healthcare Affiliated Physicians, PC.

Qualifications and experience

Treatments and Conditions

My research

Alomary SA, Baker NJ, Schell N, Ogunleye T, Taylor S, Milbar H An Analysis of TSH Levels in Patients with Nonscarring Alopecia: A Single-Center Retrospective Comparative Study , The Journal of Clinical and Aesthetic Dermatology : 2026

Baker NJ, Alomary SA, Ogunleye T, Taylor S Risk of Psychiatric Comorbidities in Non-Scarring Versus Scarring Alopecia: A Retrospective Cohort Study , J Cutan Med Surg: 2026

Alomary SA, Baker NJ, Ogunleye T, Taylor SC Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System , JAAD Int, 25: 2026,92-94

Encarnacion IN, Desir N, Schell N, Mehta A, Ogunleye T, Taylor S Visit Complexity Differs Between Scarring and Nonscarring Alopecia: A Five-Year DataDerm Analysis , J Am Acad Dermatol, S0190-9622(26): 2026

Encarnacion IN, Desir N, Anusionwu ID, Hislop C, Feldman E, Ogunleye T, Taylor S GLP-1 Receptor Agonists in Overweight and Obese Patients with Hidradenitis Suppurativa , J Drugs Dermatol, 25(2): 2026,178-80

Ogunleye TA Patient Perspectives on Scalp Biopsies for CCCA , Journal of Drugs in Dermatology Buzz Series: 2026

Desir N, Encarnacion I, Oyasiji O, Durango K, Obeng-Nyarko C, Ogunleye, Taylor S Intralesional corticosteroid injection technique for scarring and nonscarring alopecia: A cross-sectional survey of hair experts in the United States , JAAD: 2025

Anusionwu I, Durango KP, Barrera TM, Ogunleye T, Taylor SC, Mollanazar N The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients with Atopic Dermatitis: A Retrospective Chart Review , J Drugs Dermatol, 24: 2025,8749

Desir N, Encarnacion I, Ogunleye T, Taylor S Scalp pain or tenderness may offer diagnostic clues regarding cicatricial alopecia subtype , JAAD: 2025

Starks S CCCA , Allure: 2025